Use of cannabinoids in the treatment of epilepsy
US-2017007551-A1 · Jan 12, 2017 · US
Use of cannabinoids in the treatment of epilepsy
US9956185B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9956185-B2 |
| Application number | US-201715449177-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 3, 2017 |
| Priority date | Jun 17, 2014 |
| Publication date | May 1, 2018 |
| Grant date | May 1, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of reducing convulsive seizure frequency in a patient with a treatment-resistant epilepsy, which is Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol (THC); and wherein dose of the CBD is at least 15 mg/kg/day. 2. A method of reducing convulsive seizure frequency in a patient with a treatment-resistant epilepsy, which is Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol (THC), wherein the dose of the CBD is at least 10 mg/kg/day. 3. The method of claim 2 , wherein the dose of the CBD is 10 mg/kg/day. 4. The method of claim 2 , wherein the dose of the CBD is 12 mg/kg/day. 5. The method of claim 2 , wherein the dose of the CBD is 14 mg/kg/day. 6. The method of claim 2 , wherein the dose of the CBD is 15 mg/kg/day. 7. The method of claim 2 , wherein the dose of the CBD is 16 mg/kg/day. 8. The method of claim 2 , wherein the dose of the CBD is 18 mg/kg/day. 9. The method of claim 2 , wherein the dose of the CBD is 20 mg/kg/day. 10. A method of treating convulsive seizures in a patient with a treatment-resistant epilepsy, which is Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol (THC); and wherein dose of the CBD is at least 15 mg/kg/day. 11. A method of treating convulsive seizures in a patient with a treatment-resistant epilepsy, which is Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol (THC), wherein the dose of the CBD is at least 10 mg/kg/day.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
for petit-mal · CPC title
Antiepileptics; Anticonvulsants · CPC title
Drugs for disorders of the nervous system · CPC title
having two nitrogen atoms, e.g. dilazep · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9956185B2 cover?
- The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates t…
- Who is the assignee on this patent?
- Gw Pharma Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/658. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).